STIM: The Stimulation To Induce Mothers Study

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05079841
Collaborator
(none)
562
1
2
28.5
19.7

Study Details

Study Description

Brief Summary

The investigators propose a parallel group randomized clinical trial of intrapartum nipple stimulation versus exogenous oxytocin infusion for nulliparous women undergoing induction of labor near term. The central hypothesis is that intrapartum nipple stimulation to induce labor increases spontaneous vaginal delivery, improves patient-centered outcomes such as childbirth satisfaction, labor agentry, and pain scores, and reduces adverse neonatal and maternal outcomes in nulliparous women. The investigators will pursue the following specific aims: 1) Assess the effectiveness of intrapartum nipple stimulation on the rate of spontaneous vaginal delivery in nulliparous women (Primary Aim), 2) Determine the effect of intrapartum nipple stimulation on the rate of adverse maternal and neonatal outcomes (Secondary Aim #1), 3) Determine the impact of intrapartum nipple stimulation on patient-centered outcomes (Secondary Aim #2) and 4) In a sub-cohort of women who are enrolled in the trial, to measure the change in oxytocin concentration from baseline to time at which patient achieves a regular contraction pattern, and to measure correlation between salivary and serum oxytocin concentrations in patients undergoing induction of labor via intrapartum nipple stimulation versus continuous exogenous oxytocin infusion. The investigators estimate that randomizing a total of 562 women will provide adequate statistical power to detect meaningful differences in the primary outcome.

Condition or Disease Intervention/Treatment Phase
  • Device: Electric breast pump
  • Drug: Exogenous oxytocin intravenous infusion
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
562 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
The Stimulation To Induce Mothers (STIM) Study: A Parallel Group Randomized Controlled Trial
Actual Study Start Date :
Nov 15, 2021
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Apr 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intrapartum nipple stimulation

Participants randomized to the intrapartum nipple stimulation will use electric breast pump or stimulate by hand (intervention) to induce labor.

Device: Electric breast pump
Participants randomized to the intrapartum nipple stimulation will use electric breast pump or nipple stimulate by hand (if preferred) (intervention) to induce labor
Other Names:
  • Medela Symphony pump
  • Active Comparator: Exogenous oxytocin intravenous infusion

    Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor.

    Drug: Exogenous oxytocin intravenous infusion
    Participants randomized to the standard care arm will use exogenous oxytocin intravenous infusion to induce labor
    Other Names:
  • Pitocin intravenous infusion
  • Outcome Measures

    Primary Outcome Measures

    1. Spontaneous vaginal delivery [At delivery]

      Spontaneous vaginal delivery will be defined as delivery that occurs without the use of forceps, vacuum, or cesarean

    Secondary Outcome Measures

    1. Operative vaginal delivery [At delivery]

      Delivery with the assistance of forceps or vacuum, and indication

    2. Cesarean delivery [At delivery]

      Delivery by cesarean section

    3. Labor induction duration [At delivery]

      Time interval from randomization to delivery

    4. Postpartum hemorrhage [From delivery to 24 hours postpartum]

      Cumulative blood loss of ≥1,000 mL within 24 hours after the birth process

    5. Neonatal Apgar score ≤3 at 5 minutes of life [At 5 minutes after birth]

      The Neonatal Apgar score is scored from 0 to 10. A 5-minute Apgar score of 0-3 correlates with neonatal mortality in large population studies.

    6. Umbilical acidemia [At delivery]

      Umbilical cord arterial pH <7.0 or base excess >12 mmol/L; or umbilical cord venous pH <7.0 or base excess >12 mmol/L if arterial blood sample not available

    7. Neonatal Intensive Care Unit admission [up to 28 days following delivery]

      Any admission to the Neonatal Intensive Care Unit from delivery until birth hospitalization discharge or neonatal death up to 28 days of life

    8. Composite neonatal severe morbidity measure [up to 28 days following delivery]

      Intrapartum fetal death or neonatal death; cardiorespiratory support within first 72 hours of life; neonatal encephalopathy; seizures; hypothermic treatment (cooling); sepsis; pneumonia; major birth injury; meconium aspiration syndrome; intracranial hemorrhage or subgaleal hemorrhage; or hypotension requiring pressor support

    9. Lactational mastitis [After delivery to 12 weeks postpartum]

      Subject-reported occurrence of lactational mastitis

    Other Outcome Measures

    1. Subject-reported pain during childbirth [At intervention start and than again 2 hours after intervention start]

      Visual analog scale, scored with Likert scale from 0 (no pain) to 10 (worst pain)

    2. Subject-reported satisfaction during labor and childbirth [6-96 hours after delivery]

      Birth Satisfaction Scale-Revised is a 10-item self-report valid and reliable measure (scores range from 0 to 40, 0 being the least satisfaction and 40 being the most satisfaction)

    3. Subject-reported feelings of control during labor and childbirth [6-96 hours after delivery]

      Labor Agentry Scale is a 29-item survey designed to assess expectations and experiences of personal control during childbirth (scores range from 29 to 203, with higher scores indicating greater perceived control during childbirth)

    4. Subject-reported depression score [4 to 12 weeks after delivery]

      Edinburgh Postnatal Depression Scale is a 10-item self report scored from 0 to 30; score >10 warrants additional clinical assessment for depression

    5. Subject-reported breastfeeding success [4 to 12 weeks after delivery]

      Maternal Breastfeeding Evaluation Scale (MBFES) is a 30-item using a 5-point Likert scale with higher scores reflecting more positive breastfeeding experiences.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Nulliparous

    • Gestational age 36 0/7 weeks and greater at enrollment

    • Singleton gestation

    • Planned to undergo initiation of exogenous oxytocin infusion by their maternity care provider

    • Spontaneous rupture of membranes or if membranes intact, modified Bishop score ≥5 and cervix dilated <6 cm within one hour of enrollment

    • Ability to give informed consent

    Exclusion Criteria:
    • Unable to understand English or Spanish

    • Prior use of exogenous oxytocin or attempt at nipple stimulation during the current pregnancy

    • Presence of tachysystole (defined as more than 5 contractions in 10 minutes averaged over 30 minutes), recurrent variable or late fetal decelerations, and bradycardia in the prior 30 minutes before enrollment

    • Non-vertex presenting fetus at time of enrollment

    • Planned for cesarean delivery or contraindication to labor by institutional policy (e.g., placenta previa, vasa previa, active genital herpes infection, previous transmural myomectomy)

    • Multi-fetal gestation (e.g., twins, triplets, and higher-order multiples)

    • Intrauterine fetal death

    • Major fetal anomaly suspected prenatally (defined as a fetal anomaly with anticipated neonatal intensive care unit admission)

    • Suspected alloimmunization (given the increased likelihood for anticipated neonatal intensive care unit admission)

    • Known severe fetal growth restriction (estimated fetal weight <3rd percentile) or abnormal umbilical artery Doppler studies (given the increased likelihood for anticipated neonatal intensive care unit admission)

    • HIV infection (nipple stimulation is not encouraged given the recommendation for these mothers not to breastfeed)

    • Participation in another interventional study that influences management of labor and delivery or perinatal morbidity or mortality

    • History of mastectomy or other contraindication to use of electronic breast pump

    • Known allergic reactions to components of the electronic breast pump or to synthetic oxytocin intravenous solution

    • Significantly impaired consciousness or executive function (e.g., intubated or sedated)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Yale New Haven Hospital New Haven Connecticut United States 06510

    Sponsors and Collaborators

    • Yale University

    Investigators

    • Principal Investigator: Moeun Son, MD, MSCI, Yale University, Yale School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yale University
    ClinicalTrials.gov Identifier:
    NCT05079841
    Other Study ID Numbers:
    • 2000031338
    First Posted:
    Oct 15, 2021
    Last Update Posted:
    Jan 25, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 25, 2022